ViroLogic Inc. sold convertible stock for $10 million. The deal was announced March 26.
The investors included SDS Merchant Fund, DMG Legacy Fund and JALAA Equities.
South San Francisco's ViroLogic makes and produces products that test the resistance of certain viruses to drugs used to treat them. Its signature product is Phe...
The investors included SDS Merchant Fund, DMG Legacy Fund and JALAA Equities.
South San Francisco's ViroLogic makes and produces products that test the resistance of certain viruses to drugs used to treat them. Its signature product is Phe...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In




